NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine - https://archive.org/web/.

Transparency watchdog criticizes STAT’s non-disclosure on pro-Pharma op-ed

Posted By

Gary Schwitzer is the founder and publisher of HealthNewsReview. He has covered health care news almost exclusively since 1973. Here is his online bio.  He tweets as @garyschwitzer or as @HealthNewsRevu.

Should publications that post op-ed pieces tell us more about who wrote the op-ed and what their potential biases and conflicts of interest might be?

I’m in the camp that answers a resounding YES.

Till Bruckner is, too. He writes for Transparify, an organization that rates “the financial transparency of major think tanks.” He is also the founder of TranspariMED, which “works to end evidence distortion in medicine.”  His watchdog work on op-eds inspired a New York Times public editor column a few years ago, “Hidden Interests, Closer to Home.”

This week he tweeted criticism of STAT News for not disclosing more about the author of an op-ed criticizing possible Biden administration plans to evaluate drug therapies. The op-ed delivers a fearful prediction:

Patient advocates should scrutinize any “independent review board” the Biden administration commissions because it will have a conflict of interest and a bias against breakthrough therapies. In this scenario, patients may never receive a new, potentially life-changing therapy because it is rated by a biased review board as not having any “quantifiable benefit” based on its price tag alone rather than the potentially life-changing impact that it could have for patients.

That’s a sweeping and fear-mongering allegation – that any review board the new Administration will appoint will have a bias and conflict of interest.

What bias or conflict of interest does the op-ed author have?

STAT didn’t provide that background.  Readers are only told that the author is a visiting fellow at the Boston-based Pioneer Institute. (Addendum at 7:30 a.m. Feb. 12:  Readers were not told that the author, William S. Smith, according to the Institute’s website, “spent ten years at Pfizer Inc as Vice President of Public Affairs and Policy where he was responsible for Pfizer’s corporate strategies for the U.S. policy environment.”) 

What is the Pioneer Institute? Its website tells you that it is a public policy research think tank whose mission statement endorses free enterprise and free markets.  Who funds them?

Till Bruckner tweeted this graphic, and wrote that “it would have been good (for STAT) to disclose that one of the think tank’s top funders is Pfizer, especially as their op-ed mirrors industry talking points 100%.”

 

HealthNewsReview.org has criticized STAT’s op-ed policies several times over the past 3.5 years.

 

‘A blow to [STAT’s] credibility’: MD listed as author of op-ed praising drug reps didn’t write it. Ghostwriting/PR influence

Another ‘breach of trust’ at STAT: patient who praised TV drug ads says pharma PR company asked her to write op-ed

Lowering the bar on Alzheimer’s drugs: STAT op-ed takes industry-friendly line, without disclosing author’s pharma ties

In response to some of this criticism, STAT revised its guidelines for op-ed submissions. But the latest example begs the question of whether that went far enough.

To be clear, STAT delivers some terrific journalism. But in the interest of continuous quality improvement, it should re-examine its op-ed and broader conflict of interest policies again.

By the way, I have no financial conflict of interest in this matter, since I have no income from or funding for this project.

You might also like

Comments

Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.

Comments are closed.